Global Allergy Diagnostics And Therapeutics Market Size By Type (Instruments, Consumables), By Application (Diagnostic Laboratories, Hospitals), By Region, And Segment Forecasts, 2023 to 2032

The Global Allergy Diagnostics and Therapeutics Market was valued at USD 5.1 billion in 2023 and is projected to reach USD 9.4 billion by 2031, growing at a CAGR of 7.9% from 2023 to 2031. The rising prevalence of allergic disorders, growing environmental pollution, and increasing awareness regarding early diagnosis are key contributors to market growth. Moreover, advancements in allergy testing technologies and the introduction of targeted immunotherapies are accelerating the adoption of both diagnostic and therapeutic solutions across hospitals, diagnostic centers, and research institutes.

Drivers

1. Increasing Incidence of Allergic Diseases:

The surge in allergic conditions such as asthma, rhinitis, food allergies, and atopic dermatitis—largely driven by changing lifestyles and environmental factors—is fueling the demand for allergy diagnostics and treatments.

2. Technological Advancements in Allergy Testing:

Innovations such as component-resolved diagnostics (CRD), multiplex assays, and point-of-care testing devices have significantly enhanced diagnostic accuracy and patient outcomes.

3. Rise in Healthcare Expenditure:

Government initiatives and rising healthcare investments in emerging economies are enabling better access to allergy diagnostics and therapeutics, thereby supporting market growth.

Restraints

1. High Cost of Advanced Diagnostic Equipment:

Cutting-edge allergy testing tools and immunotherapies are often expensive, which may limit adoption in low-income and rural areas.

2. Lack of Skilled Professionals:

Accurate diagnosis and treatment require trained professionals; however, many regions still face a shortage of allergists and lab technicians proficient in allergy testing protocols.

Opportunity

1. Growth Potential in Emerging Markets:

The underpenetrated markets of Asia-Pacific and Latin America present substantial opportunities due to increasing allergy awareness, urbanization, and improvements in healthcare infrastructure.

2. Personalized Medicine and Immunotherapy:

The growing shift toward individualized treatment plans using biomarkers and monoclonal antibodies is opening new avenues in allergy therapeutics.

Market by System Type Insights

By system type, in vitro diagnostics dominated the market in 2023. These tests, including specific IgE blood testing and molecular diagnostics, offer high accuracy and patient comfort, especially for children. This segment is projected to maintain its lead owing to continuous technological enhancements and non-invasive nature. Meanwhile, the in vivo diagnostics segment, including skin prick tests and patch tests, also holds a significant share, especially in hospital-based settings.

Market by End-use Insights

In 2023, hospital-based laboratories emerged as the leading end-use segment, accounting for over 40% of the market share. Their wide patient base and comprehensive diagnostic infrastructure support this dominance. Diagnostic laboratories and academic research institutions are also experiencing growing adoption due to collaborative research in allergy mechanisms and therapeutic developments.

Market by Regional Insights

North America led the global market in 2023, driven by a well-established healthcare system, rising allergy awareness, and the strong presence of market leaders. However, Asia-Pacific is anticipated to register the highest CAGR during the forecast period. Factors such as increasing pollution, dietary changes, and healthcare modernization in countries like China and India are driving regional growth.

Competitive Scenario

Key players in the Global Allergy Diagnostics and Therapeutics Market include Thermo Fisher Scientific Inc., Danaher Corporation (Beckman Coulter), Siemens Healthineers, Omega Diagnostics Group PLC, Stallergenes Greer, BioMérieux SA, Anergis SA, and HOB Biotech Group Corp. These companies focus on developing novel assays, expanding geographic presence, and forming strategic partnerships to stay competitive.

Scope of Work – Global Allergy Diagnostics and Therapeutics Market

Key Market Developments

June 2024: Thermo Fisher Scientific introduced a next-gen multiplex assay panel capable of detecting over 50 allergens in a single test.

March 2023: Danaher Corporation acquired a startup specializing in AI-powered diagnostic algorithms for allergy test interpretation.

September 2022: Omega Diagnostics partnered with a leading university to develop hypoallergenic therapeutics targeting pediatric populations.

FAQs

1. What is the current market size of the Global Allergy Diagnostics and Therapeutics Market?

The market was valued at USD 5.1 billion in 2023.

2. What is the major growth driver of the Global Allergy Diagnostics and Therapeutics Market?

Rising prevalence of allergic diseases and technological innovations in diagnostics are the primary growth drivers.

3. Which is the largest region during the forecast period in the Global Allergy Diagnostics and Therapeutics Market?

North America is currently the largest market, while Asia-Pacific is expected to grow at the fastest rate.

4. Which segment accounted for the largest market share in the Global Allergy Diagnostics and Therapeutics Market?

The in vitro diagnostics segment accounted for the largest share in 2023.

5. Who are the key market players in the Global Allergy Diagnostics and Therapeutics Market?

Leading companies include Thermo Fisher Scientific, Danaher Corporation, Siemens Healthineers, and Omega Diagnostics Group.